Recce


>


Company Announcements:
(reported by the Company)
No items found
Elevator Pitch:

Recce is the creator and world leader of a major new antibiotic type: RECCE antibiotics. These soluble synthetic polymers kill "super bugs" – the worldwide danger, arising from their resistance to conventional antibiotics.

RECCE antibiotics are synthesised by an extremely simple and economic method.

RECCE antibiotics have shown in laboratory tests that they have continued activity against bacteria, even after repeated use, against both Gram-positive and Gram-negative superbugs.

Recce's antibiotics are patented and patent-pending technologies created by a world leading scientist and experienced team.

Category: Health & biotech
URL: http://www.recce.com.au/
Operational Status: Active
ASX Listing Code (if applicable): RCE
Year of Commencement: 2007
Address:

Suite 7, 3 Brodie Hall Drive
Technology Park
BENTLEY WA 6102
AUSTRALIA

State: Western Australia
Overseas Operations: No
Twitter:
Facebook:
Linkedin:
Key Personnel: Dr Graham Melrose, Michele Dilizia, James Graham, Ian Brown, Prof Dongke Zhang, Peter Williams
Awards won:
Current Period Rank:



WA Annual Rank 2016: 51

Milestones:

    December, 2017

    FDA granted Recce qualified infectious disease product designation


    July, 2017

    Started large scale production of its antibiotics at manufacturing facility in Sydney


    March, 2017

    Started animal testing of its antibitotic


    November, 2016

    Received positive toxicology results from a dose escalation study of its lead compound RECCE 327, in a mouse with cancer.


Funding:

    June, 2017

    Secured funding commitment of up to $6.1m from the Australian Special Opportunity Fund


Company News:

NOTE: Company News, Milestones and Funding are as collected by Techboard as part of our Monthly Startup Ranking

Amount Seeking:
Type of capital raise:
Pre-money valuation:
ESIC Status:
ESIC Upload:
Future Intentions:
Investment Video:
Investment Pitchdeck:
Investment URL:
Investment Phone:
Investment Email:

Leave a Reply